Advertisement
HKEX
Business

Hong Kong IPO applications surge as many in China’s Silicon Valley keen, summit hears

  • HKEX hosts summit to promote the new Chapter 18C listing regime in Shenzhen, dubbed China’s ‘Silicon Valley’

Reading Time:3 minutes
Why you can trust SCMP
View of HKEX at Exchange Square, Central.  HKEX CEO Bonnie Chan Yiting said at the HKEX Future Tech Summit in Shenzhen that many technology companies are preparing to file listing applications very soon under the new listing regime Chapter 18C. Photo: Nora Tam
Enoch Yiu

Shenzhen, widely considered China’s Silicon Valley, is brimming with technology companies eager to list in Hong Kong, where a stock exchange rule change has galvanised pre-revenue unicorns.

Hong Kong Exchanges and Clearing (HKEX), the bourse operator which runs the third largest stock exchange in Asia, is now handling 106 listing applications after 40 initial public offerings (IPOs) in the city this year. The numbers are a big jump over last year’s comparable period, which saw 73 applications and 31 IPOs.

“Hong Kong is the third largest IPO market worldwide this year in terms of number of deals,” said HKEX CEO Bonnie Chan Yiting on Thursday at the HKEX Future Tech Summit in Shenzhen. “We expected more to come, as many technology companies are preparing to file listing applications very soon under the new listing regime Chapter 18C,” she added, referring to a listing reform made last year that allows specialist technology firms to list even if they have yet to generate any sales.

Advertisement

Listing candidates in other sectors have to make at least a combined HK$80 million (US$10.2 million) of profit in the three years leading up to their share issue.

Bonnie Chan Yiting, CEO of Hong Kong Exchanges and Clearing Limited (HKEX), Central. Photo: Dickson Lee
Bonnie Chan Yiting, CEO of Hong Kong Exchanges and Clearing Limited (HKEX), Central. Photo: Dickson Lee

HKEX is promoting the Chapter 18C regime in Shenzhen after the exchange saw the first listing under the amended rules in June. Shenzhen-based QuantumPharm, an artificial intelligence (AI) drug researcher, raised HK$989.3 million in an IPO which was oversubscribed by 103 times.

Advertisement
Advertisement
Select Voice
Choose your listening speed
Get through articles 2x faster
1.25x
250 WPM
Slow
Average
Fast
1.25x